Skip to main content
OpenTrials
Completed

NCT Number: NCT00928720

Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia

The purpose of this study is to determine the effects of mild cranial electrical stimulation on pain, fatigue, sleep disturbances, perceived stress, blood pressure, and functional status in persons with fibromyalgia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Virginia Center for the Study of Complementary and Alternative Therapies

Charlottesville, Virginia, 22908, United States

About this study

Central pain networks in the brain are dysregulated in persons with fibromyalgia (FM). Thus, the investigators propose that cranial electrical stimulation (CES) that works on the brain may ameliorate symptoms of FM by interacting with the central pain networks. The specific aims of this randomized, controlled, three-group pilot study design are to: (1) determine differences in pain over time between the active CES, sham device, and usual care (UC) groups; (2) explore differences in brain activity in pain processing regions (i.e., cingulate, insula, prefrontal and somatosensory cortices, amygdala, and thalamus) between the active CES, sham device, and UC groups in a subset of 12 participants (6 in each device group); (3) determine the effects of CES on other symptoms (fatigue, sleep disturbances, depression, perceived stress) and functional status, and blood pressure over time between the active CES, sham device, and UC groups; and (4) determine the amount of influence that selected psychological factors (negative affect, catastrophizing, and other personality characteristics) have on group differences in pain, other symptoms, functional status, and brain activity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • meet the diagnostic criteria for FM established by the American College of Rheumatology
  • have initial pain level equal to or greater than 3 on a NRS 0-10
  • have stable medication use related to FM for at least 4 weeks
  • be able to read, write, and understand the English language

Exclusion criteria

(all participants):

  • pregnant or breastfeeding
  • epilepsy or history of seizures
  • presence of pacemakers and/or other implanted devices

Exclusion criteria

(subset of 12 participants who wil have fMRIs):

  • conditions that would not permit an fMRI (e.g., certain types of metal or metallic objects in body, diaphragm or intrauterine device, dermal patches, ear or eye implants, implanted electrical stimulators, artificial heart valve, implanted catheter or tube, tattoos, claustrophobia; or weight more than 275 lbs)

Treatment and study plan

CES device

Device

Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.

Other names: Alpha-Stim

Sham device

Device

The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.

Primary outcomes

  1. Pain Intensity Using Numeric Rating Scale

    Time frame: week 8

    A Numeric Rating Scale ranging from 0 (no pain) to 10 (worst pain imaginable) to capture present pain intensity

Secondary outcomes

  1. Fatigue Using Lee's Fatigue Scale

    Time frame: Week 8

    A Numeric Rating Scale ranging from 0-10 to capture present levels of fatigue using the fatigue subscale of Lee's Fatigue Scale

  2. General Sleep Disturbance Scale

    Time frame: Week 8

  3. Depression Using the CES-D

    Time frame: Week 8

  4. Perceived Stress Using Numeric Rating Scale

    Time frame: Week 8

  5. Functional Status Using the Fibromyalgia Index Questionnaire

    Time frame: Week 8

Sponsors and collaborators

Lead sponsor

University of Virginia

Other

Registry information

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jun 26, 2009
Registry last updated
Jul 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.